SAN
DIEGO, Jan. 23, 2025 /PRNewswire/
-- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced
that Andrew Ratz, Ph.D., has joined
the company as Senior Vice President of Drug Development, Delivery
and Device. In this role, Dr. Ratz will lead the continued
transformation of Neurocrine's Chemistry, Manufacturing and
Controls organization to meet the needs of the company's growing
research and development portfolio.
Dr. Ratz joins Neurocrine after a 28-year career at Eli Lilly
and Company, where he contributed to the development and successful
registration of more than 25 products across multiple therapeutic
areas and molecule modalities. Most recently, he served as Lilly's
Senior Vice President and Head of the Drug Delivery, Device and
Connected Solutions organization. He led the integrated design and
development of devices, drug-device combination products, and
packaging systems for both the biotech and small molecule
portfolios. Prior to that, Dr. Ratz was Senior Director of Process
Chemistry and Chemical Engineering and Head of Global Outsourcing
for Lilly's small molecule portfolio.
"Andy brings unparalleled leadership and experience to
Neurocrine's R&D team," Neurocrine Biosciences Chief Scientific
Officer Jude Onyia, Ph.D., said. "He
joins at a critical and exciting time for the company as we seek to
discover and develop the next generation of treatments for patients
with great needs."
"My love of science, coupled with a passion for helping people,
has always driven my professional journey," Dr. Ratz said. "The
opportunity to be part of Neurocrine, where innovation meets a
commitment to improving lives, is truly inspiring. I am excited to
contribute to the groundbreaking work being done here and to make a
lasting impact on patients' lives through science and
discovery."
Dr. Ratz received a Bachelor of Science degree in Chemistry from
Indiana University and earned his Ph.D.
in Chemistry from Harvard
University.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading neuroscience-focused,
biopharmaceutical company with a simple purpose: to relieve
suffering for people with great needs. We are dedicated to
discovering and developing life-changing treatments for patients
with under-addressed neurological, neuroendocrine and
neuropsychiatric disorders. The company's diverse portfolio
includes FDA-approved treatments for tardive dyskinesia, chorea
associated with Huntington's
disease, classic congenital adrenal hyperplasia, endometriosis* and
uterine fibroids,* as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more
information, visit neurocrine.com, and follow the company
on LinkedIn, X (formerly Twitter)
and Facebook. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/andrew-ratz-phd-joins-neurocrine-biosciences-as-senior-vice-president-of-drug-development-delivery-and-device-302358103.html
SOURCE Neurocrine Biosciences, Inc.